spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  thrombocytopenic purpura 

 HSMN NewsFeed - 1 Oct 2018
FDA Approves KYPROLIS(R) (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone (Kd70) For Patients With Relapsed Or Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Sep 2018
Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Nov 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jul 2016
European Commission Approves Extended Indication For Amgen's Kyprolis(R) (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2014
Ligand Partner GSK Announces Results of Phase 3 PETIT2 Study of Eltrombopag (Promacta(TM)/Revolade(TM)) in Pediatric Patients with Chronic Immune Thrombocytopenia
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2013
Rigel Provides Pipeline Update
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2012
Mylan Launches Generic Version of Qualaquin(R) Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 27 Jun 2012
PRIMA Study Shows Treatment with Privigen(R) Improved Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2011
Alexion Submits Applications for Soliris(R) (Eculizumab) as a Treatment for Patients with Atypical Hemolytic Uremic Syndrome (aHUS) in the United States and European Union
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2011
FDA Grants Full Approval for PROMACTA(R) (eltrombopag) for Treatment of Rare Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2010
Ligand Announces Approval for Revolade(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Oct 2010
Talecris Biotherapeutics Receives FDA Approval for Gamunex(R)-C
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2010
Privigen(R) Demonstrates Efficacy and Tolerability Among Patients With Various Immunodeficiencies, Data Show
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2009
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Aug 2009
New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 18 May 2009
FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jan 2009
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2009
Archemix Announces Continued Progress with Business Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2008
FDA Grants Approval to Talecris Biotherapeutics for Gamunex(R) as a Treatment for Neurological Disorder CIDP in the United States
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Aug 2008
FDA Approves Nplate(TM) for Long-Term Treatment of Adult Chronic ITP
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 8 May 2008
FDA Grants Priority Review of Gamunex(R) as a Treatment for Neurological Disorder CIDP
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Apr 2008
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2008
Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Mar 2008
FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2008
Positive Results from Phase III Trial of Gamunex(R) in Patients with CIDP
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2007
GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2007
Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2007
Vermillion Announces Agreement to Have Ohio State University Commercialize Diagnostic Test for Blood Disorder
Diagnostics
 HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals
 HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2007
FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 28 Aug 2007
MGI PHARMA Signs Agreement for Rights to Novel Treatment for Thrombocytopenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Jun 2007
Pivotal Phase III Trial Showed PROMACTA(R) (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2007
Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Apr 2007
BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
Biopharmaceuticals
 HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
Biopharmaceuticals
 HSMN NewsFeed - 2 Apr 2007
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Feb 2007
Protalex Appoints Edward W. Bernton, MD as Medical Director and Updates Development Plans for 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes and Improved Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2006
Ciphergen and Ohio State University Research Foundation Sign Collaborative Agreement to Develop Diagnostic Test for Blood Disorder
Diagnostics
 HSMN NewsFeed - 7 Nov 2006
Symphogen Appoints Christian Meyer Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 34

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 34 additional stories matching:
thrombocytopenic purpura
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.